Avai Bio, Inc.

AVAI: 10-Q · periodic report

Avai Bio, Inc. (formerly Avant Technologies Inc.) reported zero revenue and a net loss of $552,041 for the three months ended June 30, 2026, up 13% from a $487,589 loss a year earlier, and disclosed substantial doubt about the company's ability to continue as a going concern. The micro-cap AI holding company held just $83,586 in cash against $4.01 million in total current liabilities and a $3.22 million stockholders' deficit, and stated it needs to raise roughly $10 million to fully implement its business plan. Management concluded that disclosure controls and procedures were not effective as of June 30, 2026. During the quarter, the Ai-nova Acquisition Corp LLC joint venture with Ainnova Tech Inc. was dissolved, producing a $24,543 loss on disposal, while the company acquired the Wellness Assessment API for $58,600 and remains committed up to $1.5 million each to its Klothonova and Insulinova biotech joint ventures with SGAustria Pte. Ltd. Dilution continues: shares outstanding rose to 153,916,565, including 705,313 shares issued to convert $144,630 of accounts payable during the quarter, and the company relies on high-cost convertible notes from Boot Capital LLC and Vanquish Funding Group Inc. that carry 22% default interest rates alongside more than $800,000 of demand- payable related-party loans.

SEC 10-Q•2mo ago

AVAI: NT 10-K · late filing

Avai Bio, Inc. has notified the SEC that it will be late in filing its Annual Report on Form 10-K for the fiscal year ended March 31, 2026. The company attributed the delay to the additional time required to complete the preparation and compilation of financial statements and related disclosures. Avai Bio expects to file the report within the 15-calendar day extension period provided by Rule 12b-25 and does not anticipate a significant change in results of operations.

SEC NT 10-K•3mo ago